定期筛查供体粪便结合检疫期预防粪菌移植中多重耐药菌传播的回顾性队列研究
该回顾性队列研究评估荷兰供体粪便库筛查方案(每3个月筛查多重耐药菌,结合指征筛查和3个月检疫期)对粪菌移植中多重耐药菌传播的预防效果。
要点
- 健康供体在捐献期间可能定植多重耐药菌,需定期监测。
- 检疫期结合定期筛查可防止多重耐药菌阳性悬液用于移植。
- 获批悬液中未检出多重耐药菌,支持该筛查方案的有效性。
核心结论
- 健康粪便供体在捐献期间可能获得多重耐药菌定植。
- 该筛查方案未导致多重耐药菌阳性粪便悬液被批准用于菌群移植。
研究设计与样本
- 检测2016年12月12日至2019年5月1日期间已检疫批准的粪便悬液,使用非选择性和选择性肉汤富集培养基。
- 对所有多重耐药分离株进行全基因组测序及核心基因组多位点序列分型(cgMLST)。
主要发现
- 初始筛查中,66名受检者中6人(9%)多重耐药菌阳性;任何时间点66人中11人(17%)阳性。
- 16名活跃供体中4人(25%)检出多重耐药菌,中位捐献时长268天(IQR 92-366)。
- 所有筛查结果中,19株多重耐药菌中14株(74%)为产ESBL大肠埃希菌。
- 344份获批粪便悬液中170份(49%)有对应研究用粪便等分试样并接受检测(来自11名活跃供体,每人中位8份悬液,IQR 5-26)。
关键数值与推荐
- 供体每3个月筛查多重耐药菌,结合指征筛查(如出国旅行后),并对3个月内所有粪便悬液应用检疫期。
临床怎么用
- 粪菌移植供体应定期筛查多重耐药菌,并考虑检疫期以防止耐药菌传播。
- 对供体捐献期间的新发定植需保持监测,避免使用阳性悬液。
局限性
- 回顾性研究设计。
- 仅49%获批悬液有对应样本可供检测。
- 单中心数据,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On June 13, 2019, the US Food and Drug Administration issued a warning after transfer of faeces containing an extended-spectrum β-lactamase (ESBL)-producing Escherichia coli by faecal microbiota transplantation led to bacteraemia in two immunocompromised patients. Consequently, we evaluated the effectiveness of the faeces donor-screening protocol of the Netherlands Donor Faeces Bank, which consists of screening of donors for multidrug-resistant organisms every 3 months, combined with additional screening on indication (eg, after travelling abroad) and application of a quarantine period for all faecal suspensions delivered within those 3 months. METHODS: We did a retrospective cohort study of data collected between Jan 1, 2015, and Oct 14, 2019, on the multidrug-resistant organism testing results of donor faeces. Additionally, we tested previously quarantined faecal suspensions approved for faecal microbiota transplantation between Dec 12, 2016, and May 1, 2019, for the presence of multidrug-resistant organisms using both aselective and selective broth enrichment media. Whole-genome sequencing with core-genome multilocus sequence typing (cgMLST) was done on all multidrug-resistant isolates. FINDINGS: Among initial screenings, six (9%) of 66 tested individuals were positive for multidrug-resistant organisms and 11 (17%) of 66 tested individuals were positive for multidrug-resistant organisms at any timepoint. Multidrug-resistant organisms were detected in four (25%) of 16 active donors, who had a median donation duration of 268 days (IQR 92 to 366). Among all screening results, 14 (74%) of 19 detected multidrug-resistant organisms were ESBL-producing E coli. 170 (49%) of 344 approved faecal suspensions had corresponding research faeces aliquots available and were tested (from 11 active donors with a median of eight [IQR five to 26] suspensions per donor). No multidrug-resistant organisms were detected in the 170 approved faecal suspensions (one-sided 95% CI 0 to 1·7). cgMLST revealed that all multidrug-resistant organisms were genetically different. INTERPRETATION: Healthy faeces donors can become colonised with multidrug-resistant organisms during donation activities. Our screening protocol did not result in approval of multidrug-resistant organism-positive faecal suspensions for microbiota transplantation. FUNDING: None.
引用
- Vendrik KEW, Terveer EM, Kuijper EJ, et al. Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infect Dis. 2020. PMID: 33275940. doi:10.1016/S1473-3099(20)30473-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。